Moderna, Merck cancer vaccine scores big win in late-stage melanoma trial
Moderna and Merck's personalised mRNA vaccine met key goals in a Phase 3 melanoma trial, reducing recurrence and spread and raising hopes for a new generation of cancer vaccines worldwide
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.business-standard.com — the content belongs to Business Standard.
